Understanding the Changing Landscape of Real World Evidence Generation: Economic/Reimbursement Studies and RWE Budget: Best Practice Summary

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from "Understanding the Changing Landscape of Real World Evidence Generation: Economic/Reimbursement Studies and RWE Budget"

STUDY OVERVIEW

Real World Evidence (RWE) is a key driver of formulary and reimbursement decisions by both public and private payers and is an important focus area for global regulators. Consequently, the pharmaceutical industry has been boosting internal RWE capabilities and is increasingly outsourcing to vendors specializing in RWE generation.

Health economic modeling and health technology assessment studies are two RWE study methods that many pharma companies utilize. Best Practices, LLC conducted this study to gain insights into current and future utilization of these two study methods as well as the data collection methods used, the level of outsourcing used and valued vendor traits for these study types. The study also presents metrics on RWE budget, both internal and external (vendor).

KEY TOPICS

Executive Summary: Methodology, Participants, Recommendations & Key Findings
Overview of Health Economic/Reimbursement Study Methods Utilization, Data Collection Methods & Outsourcing
Economic/Reimbursement Studies
RWE Budget and Rationale for Outsourcing

KEY METRICS

What is your level of awareness/utilization regarding Health Economic Modeling studies?
Do you believe your usage of Health Economic Modeling will increase/decrease/stay same?
How many Health Economic Modeling studies did you conduct in the past year?
In 2020, how many Health Economic Modeling do you anticipate doing?
What methods of data collection do you use for Health Economic Modeling studies?
In 2020, what methods of data collection will you use for Health Economic Modeling studies?
To what extent do you outsource Health Economic Modeling studies?
For Health Economic Modeling studies, what is the most critical characteristic you desire in a vendor?
If you have a preferred vendor for Health Economic Modeling studies, please identify them
What is your level of awareness/utilization regarding Health Technology Assessments?
Do you believe your usage of Health Technology Assessments will increase/decrease/stay same?
How many Health Technology Assessments did you conduct in the past year?
In 2020, how many Health Technology Assessments do you anticipate doing?
What methods of data collection do you use for Health Technology Assessment studies?
In 2020, what methods of data collection will you use for Health Technology Assessment studies?
To what extent do you outsource Health Technology Assessments?
For Health Technology Assessments, what is the most critical characteristic you desire in a vendor?
If you have a preferred vendor for Health Technology Assessments, please identify them
What was your 2017 budget for real world evidence generation?
In 2020, what do you anticipate your RWE generation budget will be?
What is your rationale for using in-house resources for RWE studies?
What is your rationale for using outsourcing for RWE studies?

SAMPLE KEY FINDINGS

Economic/Reimbursement Studies: A mix of primary and secondary data is the data collection method used by a majority for both study types in this category: The combination data collection method data is used by most respondents for Health Economic Modeling (67%) and Health Economic/HTA (60%).

METHODOLOGY

This study engaged 25 leaders within 19 global organizations with deep experience in managing Real World Evidence generation at top pharmaceutical companies.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Manufacturing; Biotech; Consumer Products; Medical Device; Biopharmaceutical; Clinical Research; Laboratories

Companies Profiled:
Abbott; Abbvie; Bayer; Johnson & Johnson; Allergan; AstraZeneca; Celldex Therapeutics; Dermira; EMD Serono; Flexion; GlaxoSmithKline ; Grifols; Janssen; Novartis; Genzyme; Merck; UCB Pharma; Vifor Pharma; Sanofi

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Understanding the Changing Landscape of Real World Evidence Generation: Economic/Reimbursement Studies and RWE Budget

ID: 5516

Features:

Pages/Slides: 35

Published: Pre-2019

Delivery Format: Online PDF Document

STUDY OVERVIEW

KEY TOPICS

KEY METRICS

SAMPLE KEY FINDINGS

METHODOLOGY

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
626088C31B2FA6D4C852582B9006F546C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/changing-landscape-of-real-world-evidence-generation-economic-reimbursement-studies?OpenDocument
18
19OpenDocument
203.14.153.176
21
22
23globalbenchmarking.com
24/bestp/domrep.nsf
25DB